carbachol
Dosage Form: intraocular solution
Miostat®
(CARBACHOL INTRAOCULAR SOLUTION, USP) 0.01%
DESCRIPTION
Miostat® (carbachol intraocular solution, USP) is a sterile balanced salt solution of carbachol for intraocular injection. The active ingredient is represented by the chemical structure:
Established name:
Carbachol
Chemical name:
Ethanaminium, 2-[(aminocarbonyl)oxy]-N,N,Ntrimethyl-, chloride.
Molecular Formula: C6H15CIN2O2
Molecular Weight: 182.65
Each mL contains: Active: carbachol 0.01%.
Inactives: sodium chloride 0.64%, potassium chloride 0.075%, calcium chloride dehydrate 0.048%, magnesium chloride hexahydrate 0.03%, sodium acetate trihydrate 0.39%, sodium citrate dihydrate 0.17%, sodium hydroxide and/or hydrochloric acid (to adjust pH) and Water for Injection. pH range is 6.5-7.5.
CLINICAL PHARMACOLOGY
Carbachol is a potent cholinergic (parasympathomimetic) agent which produces constriction of the iris and ciliary body resulting in reduction in intraocular pressure. The exact mechanism by which carbachol lowers intraocular pressure is not precisely known.
INDICATIONS AND USAGE
Intraocular use for obtaining miosis during surgery. In addition, Miostat (carbachol intraocular solution, USP) reduces the intensity of intraocular pressure elevation in the first 24 hours after cataract surgery.
CONTRAINDICATIONS
Should not be used in those persons showing hypersensitivity to any of the components of this preparation.
WARNINGS
For single-dose intraocular use only. Discard unused portion. Intraocular carbachol 0.01% should be used with caution in patients with acute cardiac failure, bronchial asthma, peptic ulcer, hyperthyroidism, G.I. spasm, urinary tract obstruction and Parkinson's disease.
PRECAUTIONS
Use only if the container is undamaged.
Carcinogenesis
Studies in animals to evaluate the carcinogenic potential have not been conducted.
Pregnancy
Category C. There are no adequate and well-controlled studies in pregnant women. Miostat® (carbachol intraocular solution, USP) should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Nursing Mothers
It is not known if this medication is excreted in breast milk. Exercise caution when administering to a nursing woman.
Pediatric Use
Safety and efficacy in pediatric patients have not been established.
Geriatric Use
No overall differences in safety or effectiveness have been observed between elderly and younger patients.
ADVERSE REACTIONS
Ocular: Corneal clouding, persistent bullous keratopathy, retinal detachment and postoperative iritis following cataract extraction have been reported.
Systemic: Side effects such as flushing, sweating, epigastric distress, abdominal cramps, tightness in urinary bladder, and headache have been reported with topical or systemic application of carbachol.
DOSAGE AND ADMINISTRATION
Aseptically remove the sterile vial from the blister package by peeling the backing paper and dropping the vial onto a sterile tray. Withdraw the contents into a dry sterile syringe, and replace the needle with an atraumatic cannula prior to intraocular instillation. No more than one-half milliliter should be gently instilled into the anterior chamber for the production of satisfactory miosis. It may be instilled before or after securing sutures. Miosis is usually maximal within two to five minutes after application.
HOW SUPPLIED
In a 2.0 mL glass vial with a 1.5 mL fill, grey butyl stopper and aluminum seal packaged twelve to a carton.
NDC 0065-0023-15
STORAGE: Store at 15° - 30°C (59° - 86°F).
Rx Only
Alcon Laboratories, Inc.
Fort Worth, Texas 76134 USA
Printed in USA
© 2002, 2003 Alcon, Inc.
Revised: December 2003 340121-1203
PRINCIPAL DISPLAY PANEL
NDC 0065-0023-15
Miostat®
(CARBACHOL INTRAOCULAR
SOLUTION, USP) 0.01%
TWELVE
1.5 mL Sterile Glass Vials
Alcon®
Alcon Laboratories, Inc., Fort Worth, Texas 76134 USA
| Miostat carbachol solution | ||||||||||||||||||||||
| ||||||||||||||||||||||
| ||||||||||||||||||||||
| ||||||||||||||||||||||
| ||||||||||||||||||||||
| ||||||||||||||||||||||
| Marketing Information | |||
| Marketing Category | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
| NDA | NDA016968 | 04/15/1974 | |
| Labeler - Alcon Laboratories, Inc. (008018525) |
| Registrant - Alcon Laboratories, Inc. (008018525) |
| Establishment | |||
| Name | Address | ID/FEI | Operations |
| Alcon Laboratories, Inc. | 008018525 | MANUFACTURE | |
More Miostat resources
- Miostat Side Effects (in more detail)
- Miostat Dosage
- Miostat Use in Pregnancy & Breastfeeding
- Miostat Drug Interactions
- Miostat Support Group
- 0 Reviews for Miostat - Add your own review/rating
- Miostat Concise Consumer Information (Cerner Multum)
- Miostat Ocular MedFacts Consumer Leaflet (Wolters Kluwer)
- Carboptic Drops MedFacts Consumer Leaflet (Wolters Kluwer)
- Isopto Carbachol Advanced Consumer (Micromedex) - Includes Dosage Information
Compare Miostat with other medications
- Glaucoma
- Intraocular Hypertension
- Production of Miosis
No comments:
Post a Comment